Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 5, 2019
Daily News
December 5, 2019
- Low-Dose Aspirin Might Cut Dementia Risks in Diabetes Women: Researchers
December 5, 2019
- With PMD Law Amended, Japan Pharma Industry Revs Up Work for Electronic Distribution of Prescribing Info
December 5, 2019
- Course of Govt’s “All-Generation” Social Security Reform Could Impact Pharma
December 5, 2019
- Amended PMD Law Promulgated, 3-Step Enforcement to Begin Next Year
December 5, 2019
- Minutes Released for PAFSC's Aug. 29 Meeting, but Most of Discussion on Ono’s Cachexia Drug Undisclosed
December 5, 2019
- Boston Biomedical Ties Up with 3 Institutions in Oncology Research
December 5, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…